-
2026-10-10
GenSci's Oncology Innovation: NDA Approval Secured for Prostate CancerLearn More
-
2026-10-09
GenSci's Two Innovations Received IND Clearance from NMPALearn More
-
2026-09-03
GenSci Showcases Innovation at CPHI Korea 2026Learn More
-
2026-08-13
GenSci's Ophthalmology Pipeline: IND Approval Secured for Three IndicationsLearn More
-
2026-07-31
GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPALearn More
-
2024-09-03
GenSci Invites You to Meet Us at Pharmedi Vietnam 2024Learn More
-
2024-08-29
GenSci098 Injection Obtains Implied License For Clinical Trials of FDALearn More
-
2024-08-21
Jintrolong® New Dosage Form of Long-acting Somatropin Injection ApprovedLearn More
-
2024-08-06
Clinical Trial Commencement of GenSci098 Injection ApprovedPreclinical data indicate GenSci098 has the potential to become a new treatment for Thyroid Eye Disease
Learn More
-
2024-07-26
Zhejiang University – GenSci Joint Research Center of Children’s Health establishedLearn More
-
2024-07-23
NMPA: New Drug Application of Recombinant Human Follicle-Stimulating Hormone - CTP Fusion Protein Injection AcceptedThis product will potentially enhance convenience and patient compliance
Learn More